PEG-MGF
PEG-MGF research profile placeholder. Compare providers, review literature notes, and explore related goals.
- Research
- Educational
GLP-1
Slows gastric emptying and reduces appetite signals.
GIP
Supports insulin response and metabolic efficiency.
Glucagon
Increases energy expenditure and fat oxidation.
What is PEG-MGF?
Retatrutide is an investigational triple agonist that simultaneously targets GLP-1, GIP, and glucagon receptors. It has been studied as a once-weekly subcutaneous injection in Phase 2 and Phase 3 trials, with doses ranging from 1 mg to 12 mg.
Type
Peptide
Starting Dose
2 mg weekly
Max Studied
12 mg weekly
Development
Phase 3 Trials
How It Works
PEG-MGF engages multiple pathways that together support appetite control, metabolic efficiency, and fat oxidation.
GLP-1 Agonist
- ✓Reduces hunger cues
- ✓Slows gastric emptying
- ✓Improves glycemic control
GIP Agonist
- ✓Enhances insulin response
- ✓Supports nutrient partitioning
- ✓Complements GLP-1 effects
Glucagon Agonist
- ✓Raises energy expenditure
- ✓Increases fat oxidation
- ✓Supports metabolic rate
Result
Reduced Calorie Intake
Increased Fat Burning
Significant Weight Loss
Expected Results Over Time
How PEG-MGF Compares
| Feature | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptor Activity | GIP + GLP-1 + glucagon | GIP + GLP-1 | GLP-1 |
| Typical Frequency | Weekly | Weekly | Weekly |
| Regulatory Status | Investigational | FDA approved (certain indications) | FDA approved (certain indications) |
| Phase 2 avg. loss (top dose) | 24.2% @ 48 wks | — | — |
Side Effects
Commonly discussed effects in research summaries include mild gastrointestinal symptoms (nausea, reduced appetite). Always follow a qualified clinician's protocol. This page is educational only.
Dosage
Research protocols often use once-weekly subcutaneous administration with gradual titration. Use the Dosage Calculator to explore reconstitution math for your vial size.
Stay updated on the latest peptide research
New studies and guides delivered to your inbox.